HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.

Abstract
The Southeastern Cancer Study Group, in a prospectively randomized study involving patients with advanced breast cancer, has compared a low dose intermittently administered five-drug regimen including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) with an aggressively administered three-drug regimen including cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF). CAF induced more responses and more complete responses and a longer duration of disease control. However, only a marginal difference was demonstrated in overall survival between the two regimens (p = less than 0.10). Patients with a good risk pattern of metastases, i.e. those with nodular local chest wall recurrence, nodular pulmonary metastases, or bone-only metastases were more likely to achieve a response and survive longer than those with a poor risk pattern, i.e. lymphangitic pulmonary metastases, pleural effusion with chest wall ulceration, or widespread metastases, including hepatic. All of the differences between the two regimens were noted in the good risk pattern groups. CAF provided no additional benefit to patients presenting with poor risk patterns of metastases. Adriamycin-containing combinations may achieve a greater degree of tumor cell kill in certain subsets of patients with advanced breast cancer, but this provides only a marginal increase in survival.
AuthorsR V Smalley, J Lefante, A Bartolucci, J Carpenter, C Vogel, S Krauss
JournalBreast cancer research and treatment (Breast Cancer Res Treat) Vol. 3 Issue 2 Pg. 209-20 ( 1983) ISSN: 0167-6806 [Print] Netherlands
PMID6688538 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Fluorouracil
  • Prednisone
  • Methotrexate
Topics
  • Antineoplastic Agents (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Neoplasms (drug therapy, secondary)
  • Breast Neoplasms (drug therapy, mortality)
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Drug Therapy, Combination
  • Female
  • Fluorouracil (administration & dosage)
  • Humans
  • Methotrexate (administration & dosage)
  • Neoplasm Staging
  • Prednisone (administration & dosage)
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: